

# Journal of Visualized Experiments

## Highly efficient RNA-based reprogramming of human primary fibroblasts into induced pluripotent stem cells --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58687R1
Full Title:	Highly efficient RNA-based reprogramming of human primary fibroblasts into induced pluripotent stem cells
Keywords:	induced pluripotent stem cells, iPSCs, reprogramming, human, modified mRNAs, clinically relevant, microRNAs, miRNAs, fibroblasts
Corresponding Author:	Ganna Bilousova
Corresponding Author's Institution:	
Corresponding Author E-Mail:	Ganna.Bilousova@ucdenver.edu
Order of Authors:	Patrick S. McGrath Nicole Diette Igor Kogut Ganna Bilousova
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Aurora, Colorado, USA





School of Medicine

Charles C. Gates Center for  
Regenerative Medicine

12800 East 19<sup>th</sup> Avenue  
Mail Stop 8320  
Aurora, CO 80045  
United States of America

**m** 303 724 3050

**f** 303 724 3051

August 8th, 2018

Vineeta Bajaj, Ph.D.  
Review Editor  
JoVE

Dear Dr. Vineeta Bajaj,

Thank you for the opportunity to modify and resubmit this manuscript. We would like to thank the editorial board and the reviewers for great comments and suggestions that significantly improved our manuscript. Enclosed please find our revised manuscript entitled “Highly efficient RNA-based reprogramming of human primary fibroblasts into induced pluripotent stem cells” that we modified according to the editorial requests. We have also addressed the concerns raised by the reviewers. Our point-by-point response to editorial requests and peer review comments are included in a separate file.

We are looking forward to your final acceptance of the manuscript.

Sincerely,

A handwritten signature in black ink, appearing to read 'Ganna Bilousova', with a stylized flourish at the end.

Ganna Bilousova, Ph.D.  
Assistant Professor  
Department of Dermatology, Charles C. Gates Center for Regenerative Medicine,  
Director, Stem Cell Biobank and Disease Modeling Core  
303-724-3957  
[Ganna.Bilousova@ucdenver.edu](mailto:Ganna.Bilousova@ucdenver.edu)

**TITLE:**

RNA-Based Reprogramming of Human Primary Fibroblasts into Induced Pluripotent Stem Cells

**AUTHORS & AFFILIATIONS:**

Patrick S. McGrath<sup>1,2,3</sup>, Nicole Diette<sup>1,2</sup>, Igor Kogut<sup>1,2,3</sup>, Ganna Bilousova<sup>1,2,3</sup>

<sup>1</sup>Department of Dermatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA

<sup>2</sup>Charles C. Gates Center for Regenerative Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA

<sup>3</sup>Stem Cell Biobank and Disease Modeling Core, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA

**Corresponding Author:**

Ganna Bilousova (Ganna.Bilousova@ucdenver.edu)

Tel: 1-303-724-3957

**Email Addresses of Co-authors:**

Patrick S. McGrath (Patrick.McGrath@ucdenver.edu)

Nicole Diette (Nicole.Diette@ucdenver.edu)

Igor Kogut (Igor.Kogut@ucdenver.edu)

**KEYWORDS:**

Induced pluripotent stem cells (iPSCs), reprogramming, human, modified mRNAs, clinically relevant, microRNAs (miRNAs), fibroblasts

**SUMMARY:**

Here we describe a clinically relevant, high-efficiency, feeder-free method to reprogram human primary fibroblasts into induced pluripotent stem cells using modified mRNAs encoding reprogramming factors and mature microRNA-367/302 mimics. Also included are methods to assess reprogramming efficiency, expand clonal iPSC colonies, and confirm expression of the pluripotency marker TRA-1-60.

**ABSTRACT:**

Induced pluripotent stem cells (iPSCs) have proven to be a valuable tool to study human development and disease. Further advancing iPSCs as a regenerative therapeutic requires a safe, robust, and expedient reprogramming protocol. Here, we present a clinically relevant, step-by-step protocol for the extremely high-efficiency reprogramming of human dermal fibroblasts into iPSCs using a non-integrating approach. The core of the protocol consists of expressing pluripotency factors (SOX2, KLF4, cMYC, LIN28A, NANOG, OCT4-MyoD fusion) from *in vitro* transcribed messenger RNAs synthesized with modified nucleotides (modified mRNAs). The reprogramming modified mRNAs are transfected into primary fibroblasts every 48 h together with mature embryonic stem cell-specific microRNA-367/302 mimics for two weeks. The resulting iPSC colonies can then be isolated and directly expanded in feeder-free conditions. To

maximize efficiency and consistency of our reprogramming protocol across fibroblast samples, we have optimized various parameters including the RNA transfection regimen, timing of transfections, culture conditions, and seeding densities. Importantly, our method generates high-quality iPSCs from most fibroblast sources, including difficult-to-reprogram diseased, aged, and/or senescent samples.

## INTRODUCTION:

Reprogramming somatic cells into induced pluripotent stem cells (iPSCs) requires extended expression of a core set of transcription factors that are important in maintaining pluripotency<sup>1,2</sup>. When producing iPSCs for clinical applications, it is essential that the mutational burden in input cells is minimized during processing and the efficiency of iPSC generation is maintained at a relatively high level across patient samples. However, the majority of reprogramming methods, including integration-free protocols, suffers from very low reprogramming efficiencies, which limit clinical usefulness of these approaches<sup>3</sup>. The low reprogramming efficiency may also promote selective reprogramming of cells carrying preexisting mutations, increasing mutational burden in resulting iPSCs. In addition, all DNA-based reprogramming methods, such as lentivirus- and episomal-based approaches, suffer from the safety concern that DNA may randomly integrate into the genome and create the opportunity for harmful insertional mutagenesis and unwanted (potentially oncogenic) expression of pluripotency genes in downstream tissue derivatives<sup>4</sup>.

A promising approach to achieve efficient induction of pluripotency in somatic cells and reduce mutational burden in resulting iPSCs is to use synthetic capped messenger RNAs containing modified nucleobases (modified mRNAs) for reprogramming<sup>5</sup>. The efficiency of modified mRNA-based reprogramming approaches can be further enhanced by adding embryonic stem cell (ESC)-specific microRNAs (miRNAs)-367/302s<sup>3</sup>, which have been shown to reprogram somatic cells with increased efficiency<sup>6,7</sup>. However, even with the addition of miRNAs-367/302s, the modified mRNA-based reprogramming approach often fails during application to freshly isolated patient cells<sup>3</sup>. To address inconsistencies of this modified mRNA-based approach, we have recently reported an optimized, integration-free strategy that induces pluripotency in human primary fibroblasts with a high success rate and utilizes both modified mRNAs encoding reprogramming factors and mature miRNA-367/302 mimics<sup>8</sup>. In our method, the reprogramming modified mRNA cocktail includes a modified version of OCT4 fused with the MyoD transactivation domain (called M<sub>3</sub>O)<sup>9</sup> and five other reprogramming factors (SOX2, KLF4, cMYC, LIN28A, and NANOG). Combining the modified mRNA encoding the pluripotency factors with the miRNA mimics appeared to have a synergistic effect on reprogramming efficiencies in this protocol. Additional optimizations of the RNA transfection regimen, cell seeding, and culturing conditions were also necessary to increase reprogramming efficiency of the approach to an ultra-high level<sup>8</sup>.

Unlike many other protocols, our reprogramming approach typically requires only a few thousand input fibroblasts. In addition, many common non-integrating strategies using episomal plasmids, Sendai virus, or self-replicating RNA involve extensive passaging to dilute the reprogramming vector in generated iPSCs. Conversely, modified mRNA and mature miRNA mimics have a short half-life and are rapidly eliminated from cells. Taken together, the amount

of cumulative cell culture time between collecting patient samples and the generation of usable iPSCs is minimal in this approach, effectively limiting mutation accumulation in resulting iPSCs and improving cost-effectiveness.

Here, we present the detailed step-by-step protocol to achieve high-efficiency reprogramming of adult human fibroblasts into iPSCs using our combinatorial modified mRNA/miRNA-based approach<sup>8</sup>. This RNA-based reprogramming protocol provides a straightforward, cost-effective, and robust method for generating integration-free iPSCs for research and potential clinical applications. Furthermore, it is applicable to the reprogramming of a variety of fibroblast lines including difficult-to-reprogram, disease-associated, aged, and senescent fibroblasts. A schematic of the protocol for reprogramming human fibroblasts is shown in **Figure 1**. The protocol specifically describes a method for reprogramming three wells of human adult primary fibroblasts in a 6-well format plate. Two wells typically yield a sufficient number of high-quality iPSC colonies. In many cases, only one well is necessary, and the third well can be used for analysis of reprogramming efficiency. If required, the number of wells can be scaled up.

## **PROTOCOL:**

Work under RNase-free conditions and use aseptic techniques when possible. Perform all cell culture-related manipulations in a biological safety cabinet using aseptic techniques. Follow institutional biosafety standards for work with human cells.

### **1. Reagents and Equipment for Preparation of Reprogramming Initiation**

#### **1.1. Prepare the modified-mRNA cocktail encoding reprogramming factors.**

1.1.1. Follow the previously published protocol<sup>10</sup> to perform *in vitro* transcription, capping, and dephosphorylation procedures for each modified mRNA encoding individual reprogramming factor. After the final purification step, elute the modified mRNA with nuclease-free water, supplement the purified modified mRNA solution with 1 U/ $\mu$ L RNase inhibitor, quantitate the modified mRNAs using a spectrophotometer, and store at -80 °C for up to 6 months. Prepare multiple aliquots of each modified mRNA to minimize the number of freeze-thaw cycles.

Note: Similar protocols for modified mRNA production have been reported elsewhere<sup>5,8,11</sup>. Templates for *in vitro* transcription can be generated by PCR amplification from corresponding plasmid templates using primers listed in the **Table of Materials** according to the previously published protocol<sup>10</sup>. Plasmid templates for each reprogramming factor (M<sub>3</sub>O<sup>9</sup>, SOX2, KLF4, cMYC, NANOG, LIN28A) and mWasabi (control for transfection) are available from commercial sources.

1.1.2. Mix together all the modified mRNAs at a molar ratio of 3:1:1:1:1:1 (M<sub>3</sub>O : SOX2 : KLF4 : cMYC : NANOG : LIN28A) and include 10% mWasabi modified mRNA as a control for the transfection efficiency. Adjust the concentration of the complete modified mRNA reprogramming mix to a final concentration of 100 ng/ $\mu$ L by adding nuclease-free water

supplemented with 1 U/ $\mu$ L RNase inhibitor. Prepare seven 33  $\mu$ L aliquots of the complete modified mRNA cocktail. Store the mixed reprogramming aliquots at -80  $^{\circ}$ C.

Note: For each transfection, 1,000 ng of the modified mRNA cocktail is added per well (*i.e.*, a total of 3,000 ng for 3 wells). Each 33  $\mu$ L aliquot is sized to transfect 3 wells of a 6-well format plate and includes 3  $\mu$ L of excess volume to account for pipetting errors. Preparing seven 33  $\mu$ L aliquots is sufficient to complete a full fibroblast reprogramming of 3 wells in a 6-well format plate.

## 1.2. Prepare the cocktail of reprogramming miRNA mimics.

1.2.1. Dissolve lyophilized miRNA mimics (Syn-hsa-miR-302a-3p, Syn-hsa-miR-302b-3p, Syn-hsa-miR-302c-3p, Syn-hsa-miR-302d-3p, Syn-hsa-miR-367-3p) to a 5 pmol/ $\mu$ L (5  $\mu$ M) final concentration in nuclease-free water supplemented with 1 U/ $\mu$ L of RNase inhibitor. Prepare multiple aliquots of each miRNA mimic and store at -80  $^{\circ}$ C for long term storage.

1.2.2. Mix all miRNA mimics in a 1:1:1:1:1 molar ratio to a final concentration of 5 pmol/ $\mu$ L (5  $\mu$ M). Prepare seven 14  $\mu$ L aliquots of the miRNA mimics mix. Store the mixed aliquots at -80  $^{\circ}$ C.

Note: For each transfection, 20 pmol of the miRNA mimics mix is added per well (*i.e.*, a total of 60 pmol for 3 wells). Each 14  $\mu$ L aliquot is sized to transfect 3 wells of a 6-well format plate and includes 2  $\mu$ L of excess volume to account for pipetting errors. Preparing seven 14  $\mu$ L aliquots is sufficient to complete a full fibroblast reprogramming of 3 wells in a 6-well format plate.

## 1.3. Prepare the transfection buffer.

1.3.1. Pre-warm one 500 mL bottle and one 100 mL bottle of fresh reduced-serum medium to RT (RT) for approximately 2 h. Do not use a water bath.

1.3.2. Transfer a pH meter to a biosafety cabinet. Wash the meter's glass electrode with nuclease-free water. Calibrate the pH meter according to the manufacture's instructions. Wash the electrode again with nuclease-free water.

1.3.3. Transfer both bottles of reduced-serum medium into the biosafety cabinet. Use the 500 mL RT bottle to adjust the pH.

1.3.4. Measure the base pH of the reduced-serum medium by inserting the pH meter's glass electrode into the buffer. Wait up to 1 min before reading the pH on the meter.

1.3.5. Add 3-4 mL of 1 M NaOH into 500 mL of reduced-serum medium, close the bottle, and mix well. Wait up to 5 min before opening the bottle for pH measurement. Insert the pH meter's electrode into the buffer and wait until the reading on the pH meter stabilizes.

1.3.6. Continue adding small volumes of 1 M NaOH until the pH of reduced-serum medium reaches 8.15-8.17. Calibrate the pH meter several times during the process. If at any point the

pH becomes higher than 8.18, reduce it by adding fresh reduced-serum medium from the pre-warmed 100 mL bottle (step 1.3.1).

Note: The pH of the reduced-serum medium-based transfection buffer is critical. Reprogramming will be successful if the pH of the transfection buffer is about  $8.2 \pm 0.05$  but may fail if the pH is higher than 8.25. Therefore, it is advised to stop adding NaOH once the buffer's pH reaches 8.15-8.17. This will ensure that the final pH of the transfection buffer is approximately 8.2-8.22 after sterilization. The exposure of the transfection buffer to atmospheric air during the preparation of aliquots increases its pH, as well.

**1.3.7. Filter sterilize the transfection buffer using a 0.22  $\mu$ m vacuum filtration system. Aliquot the sterilized buffer into 5 or 15 mL tubes with minimal air space.**

1.3.8. Store aliquots of the transfection buffer for up to 3 months at 4 °C. Measure the pH of the aliquots periodically. Discard the aliquots if the pH is higher than 8.25. Limit aliquot usage to 2 transfections only.

1.4. Prepare the fibroblast expansion medium (FEM): minimum essential medium supplemented with 10% fetal bovine serum (FBS), 1x non-essential amino acids, 1x glutamine supplement, 55  $\mu$ M 2-mercaptoethanol, 1x pen/strep/fungizone. Store the FEM at 4 °C.

1.5. Prepare the reprogramming medium: DMEM/F12 (no HEPES) supplemented with 20% knockout serum replacement (KOSR), 0.5x non-essential amino acids, 0.5x glutamine supplement, 55  $\mu$ M 2-mercaptoethanol, 50  $\mu$ g/mL ascorbic acid, 1x pen/strep/fungizone, 100 ng/mL bFGF, and 200 ng/mL B18R. Prepare the medium at the initiation of reprogramming without bFGF and B18R, and store it at 4 °C. Do not use it beyond 1 month following preparation. Add bFGF and B18R immediately before each use to an aliquot sized for that day's use.

1.6. Prepare the plating medium by adding 5% heat-inactivated (HI) FBS into the reprogramming medium containing 20% KOSR without bFGF and B18R from step 1.5. Prepare the medium fresh on the day of intended use. Add bFGF and B18R immediately before use on day 0 of reprogramming.

1.7. Calibrate the tissue culture incubators before initiating reprogramming according to the manufacturer's instructions using a handheld digital CO<sub>2</sub> analyzer. Use a low-O<sub>2</sub> incubator for the reprogramming steps to ensure successful iPSC generation.

## **2. Culturing Fibroblasts for Reprogramming**

2.1. Prepare fibroblasts prior to the initiation of reprogramming (day -2).

2.1.1. Coat a new 10 cm tissue culture plate with 5 mL of 0.1% gelatin. Tap or swirl the plate to ensure that the entire surface is coated. Incubate for 15 min at 37 °C. Aspirate gelatin and add 10 mL of FEM. Set aside. Do not allow the coated surface of the plate to dry before adding FEM.

2.1.2. Carefully aspirate the spent medium from the fibroblasts. Rinse the cells once with 5 mL of DPBS to remove the residual serum. Add 3 mL of trypsin-EDTA. Gently rock the plate to ensure complete coverage over the cells.

2.1.3. Aspirate excess fluid, leaving ~500  $\mu$ L of trypsin. Do not over-aspirate, since this can dry and kill the fibroblasts. Incubate the fibroblasts with trypsin-EDTA for 3 min at 37 °C.

2.1.4. Remove the plate from the incubator and firmly but gently tap the side of the plate to dislodge the cells. Check the cells under the microscope. If the cells are detached and floating, proceed. If the cells are still attached, incubate for another 3 min.

2.1.5. Quickly rinse/collect the detached cells using 5 mL of FEM to neutralize the trypsin-EDTA. Move the fibroblast suspension into a 15 mL conical tube. Ensure that the cells are well-mixed.

2.1.6. Gently mix the cell suspension to break large clumps of cells, then count them on a hemocytometer. Transfer  $2.5 \times 10^5$  cells into the gelatin-coated 10-cm dish prepared in step 2.1.1. Incubate the cells overnight in the 37 °C, 5% CO<sub>2</sub> humidified regular tissue culture incubator.

Note: The cell density is critical to achieve high reprogramming efficiency, as it is important that the fibroblasts are healthy and rapidly dividing. Plating  $2.5 \times 10^5$  cells yields a 40-60% confluency 2 days later for most fibroblast samples. Adjust the amount accordingly for diseased or senescent cells to attain the desired 40-60% confluency 48 h later.

2.1.7. Replace the medium with 10 mL of fresh FEM the following day (day -1).

## 2.2. Plate the fibroblasts to initiate reprogramming (day 0).

2.2.1. Verify that the fibroblasts to be reprogrammed are at 40-60% confluency (Figure 2, day 0). If the cells are over- or under-confluent, passage the fibroblasts as described in step 2.1 and adjust the plating density accordingly. Culture for another 2 days.

2.2.2. Transfer 4 mL of DPBS into a 15 mL conical tube. Add 100  $\mu$ L of recombinant human (rh) laminin-521. Pipette up and down to mix thoroughly.

2.2.3. Pipette 1 mL of diluted rhLaminin-521 into 3 wells of a 6-well plate. Incubate the coated plate at 37 °C for 2 h.

2.2.4. Warm 6 mL of FEM and 4 mL of plating medium to 37 °C. Supplement the plating medium with bFGF at a final concentration of 100 ng/mL and B18R at a final concentration of 200 ng/mL.

2.2.5. Carefully aspirate the spent medium from fibroblasts (step 2.2.1). Rinse the cells with 5 mL of DPBS and add 3 mL of trypsin-EDTA. Gently rock the plate to cover the cells with trypsin-EDTA.

2.2.6. Aspirate excess fluid, leaving ~500  $\mu$ L of trypsin, as done in step 2.1.4. Incubate the fibroblasts with trypsin-EDTA for 3 min at 37 °C. Remove the plate from the incubator and firmly but gently tap the side of the plate to dislodge cells. Check the cells under the microscope. If the cells are detached and floating, proceed. If the cells are still attached, incubate for another 3 min.

2.2.7. Rinse/collect the detached cells using 5 mL of FEM to neutralize the trypsin-EDTA. Move the fibroblast suspension into a 15 mL conical tube. Ensure that the cells are well-mixed and count them on a hemocytometer. Pipette 12,000 cells into 4 mL of prewarmed plating medium from step 2.2.4.

Note: Do not centrifuge the cells at any point. The number of plated cells can be adjusted up or down as required for slow- or fast-growing lines, respectively.

2.2.8. Remove the coated plate from the incubator and aspirate diluted rhLaminin-521 from the coated wells. Do not allow the surface of the wells to dry. Gently resuspend cells in the plating medium. Pipette 1 mL of cell suspension into each coated well (*i.e.*, 3,000 cells per well).

2.2.9. Place the plated cells into a tri-gas tissue culture incubator with O<sub>2</sub> set to 5% (low-O<sub>2</sub>). Once the plate is set down, gently but thoroughly disperse cells by alternating between an up/down then left/right motion. Repeat the motions 2 more times. Incubate the cells overnight. Do not swirl the plate to mix.

2.2.10. Pipette 4 mL of reprogramming medium to a 15 mL conical tube and place it in the low-O<sub>2</sub> incubator with a loosened cap to equilibrate overnight. Do not add bFGF and B18R until the following day.

### 3. Initiation of Reprogramming (day 1)

Note: Once the reprogramming is initiated, daily maintenance is required for approximately 1 month. Be sure to plan accordingly. All subsequent cell incubations must be performed under low-O<sub>2</sub> conditions in the 37 °C, 5% CO<sub>2</sub>, 5% O<sub>2</sub> humidified tri-gas tissue culture incubator.

#### 3.1. Replace the plating medium at least 1 h prior to transfection.

3.1.1. Remove the equilibrated reprogramming medium from the low-O<sub>2</sub> incubator. Add bFGF to a final concentration of 100 ng/mL and B18R to a final concentration of 200 ng/mL. Mix well.

3.1.2. Proceeding with 1 well at a time, use a 1 mL pipette to remove the spent medium and replace it with 1 mL of reprogramming medium supplemented with bFGF and B18R. Repeat this for each well. Do not use vacuum aspiration, which excessively dries the cells, causes stress, and reduces reprogramming efficiency. Move the plate with cells back into the low-O<sub>2</sub> incubator.

3.2. Transfect fibroblasts with 5  $\mu$ L of RNAiMax transfection reagent per 1  $\mu$ g of modified mRNA, and 1  $\mu$ L of the transfection reagent per 6 pmol of miRNA mimics per transfection.



Note: Optimal results are obtained when transfections proceed for 16-20 h. The transfection reagent is diluted 10x; the 100 ng/ $\mu$ L modified mRNA cocktail is diluted 5x; and the 5 pmol/ $\mu$ L miRNA mimics mix is diluted 8.33x with the transfection buffer prior to complexation. See **Table 1** for a summary of the transfection setup.

**[Place Table 1 here]**

3.2.1. While preparing the transfection mixes, minimize potential exposure of reagents to RNase by following standard laboratory practice.

3.2.2. Equilibrate an aliquot of the transfection buffer (step 1.3) for approximately 1 h at RT. Do not use a 37 °C water bath or incubator to warm up the transfection buffer.

3.2.3. Remove a single aliquot of modified mRNAs (33  $\mu$ L) and miRNA mimics (14  $\mu$ L) from -80 °C and warm them to RT. Do not thaw the aliquots at 37 °C. Spin them down briefly in a microfuge.

3.2.4. Warm the transfection reagent to RT. Do not use a 37 °C water bath or incubator. Invert the closed tube 2-3 times to mix the reagent. Spin it down briefly in a microfuge.

3.2.5. Transfer 279  $\mu$ L of the RT transfection buffer into an RNase-free microcentrifuge tube. Add 31  $\mu$ L of the transfection reagent to achieve a final volume of 310  $\mu$ L. Mix thoroughly by pipetting. Do not vortex. Incubate the tube at RT for 1 min.

Note: This volume of the diluted transfection reagent is sufficient to complex both the modified mRNA and miRNA mimics aliquots from step 3.2.3.

3.2.6. Add 132  $\mu$ L of the RT transfection buffer to the 33  $\mu$ L aliquot of modified mRNA. Gently pipette to mix: final volume is 165  $\mu$ L.

3.2.7. Add 102.6  $\mu$ L of the RT transfection buffer to the 14  $\mu$ L aliquot of miRNA mimics. Gently pipette to mix: final volume is 116.6  $\mu$ L.

3.2.8. Add 165  $\mu$ L of the diluted transfection reagent from step 3.2.5 to the diluted modified mRNA from step 3.2.6. Pipette to mix: final volume is 330  $\mu$ L.

3.2.9. Add 116.6  $\mu$ L of the diluted transfection reagent from step 3.2.5 to the diluted miRNA mimics mix from step 3.2.7. Mix well (final volume is 233.2  $\mu$ L). Incubate for 15 min at RT to allow the transfection buffer to complex with the modified mRNAs and miRNA mimics.

3.2.10. Remove the plate with cells from the low-O<sub>2</sub> incubator. Add 100  $\mu$ L (1  $\mu$ g) of the complexed modified mRNA transfection mix to each well, dropwise across the well. Disperse the transfection complexes by gently but thoroughly agitating the plate with an up/down then left/right motion. Do not swirl the plate to mix.

3.2.11. Add 66.7  $\mu$ L (20 pmol) of the complexed miRNA mimics transfection mix to each well, dropwise across the well. Disperse transfection complexes by gently but thoroughly agitating the plate with an up/down then left/right motion. Do not swirl the plate to mix.

3.2.12. Place the transfected cells into the tri-gas incubator with O<sub>2</sub> set to 5% (low-O<sub>2</sub>). Once the plate is set down, disperse the transfection complexes again by gently but thoroughly agitating the plate with an up/down then left/right motion.

3.2.13. Pipette 4 mL of reprogramming medium into a 15 mL conical tube and place it in the low-O<sub>2</sub> incubator with loosened cap to equilibrate overnight. Do not add bFGF and B18R until the following day.

#### **4. Replacing Reprogramming Medium between Transfections (days 2, 4, 6, 8, 10, and 12)**

4.1. Replace the medium 16-20 h post-transfection as described in 3.1.1–3.1.2. Add bFGF to a final concentration of 100 ng/mL and B18R to a final concentration of 200 ng/mL into reprogramming medium aliquots.

4.2. Monitor mWasabi expression daily to confirm transfection quality using a microscope configured to visualize EGFP.

Note: mWasabi expression should be minimally apparent on day 2 and increase in brightness with each additional transfection.

#### **5. Every-Other-Day Transfections (days 3, 5, 7, 9, 11, and 13)**

5.1. Perform the transfection as described in step 3.2. Do not change the medium on days of transfection.

5.2. Prepare a 4 mL aliquot of reprogramming medium and place it in the low-O<sub>2</sub> incubator to equilibrate for the medium change on the following day. Do not add bFGF and B18R until the following day.

#### **6. Procedures to be Performed after Final Transfection**

6.1. Perform daily medium changes from day 14 through approximately day 17. Warm 7 mL of reprogramming medium to 37 °C. Add bFGF to a final concentration of 100 ng/mL.

Note: B18R is no longer necessary after the final transfection. Beyond day 14, it is no longer necessary to equilibrate the medium overnight in the low-O<sub>2</sub> incubator.

6.2. Remove the medium from all wells using a serological pipette. Continue to avoid using aspiration. Add 2 mL of reprogramming medium supplemented with bFGF per well.

6.3. On days 17 and 18, analyze the reprogrammed wells under an inverted or dissecting microscope. If colonies are formed in close proximity to each other due to high efficiency of reprogramming and cannot be manually isolated, separate the colonies by performing an optional passaging of reprogrammed wells described in step 7 below. If colonies are sparse and well-separated, manually pick the clones directly from the reprogrammed well as described in step 8 and subculture iPSCs according to standard protocols.

## **7. Optional Procedure: Passaging Cells from Reprogrammed Wells using EDTA**

7.1. Prepare 0.5 mM EDTA in DPBS (EDTA) by diluting the 0.5 M EDTA stock solution. Filter sterilize EDTA using a 0.22  $\mu$ m vacuum filtration system.

7.2. Prepare feeder-free pluripotent stem cell (PSC) medium (*e.g.*, mTeSR1) according to the manufacturer's instructions. Pre-warm 32 mL of PSC medium to 37 °C.

7.3. Coat all wells of two 6-well format plates with hESC-qualified extracellular matrix (ECM) following the manufacturer's instructions. Seal plates with paraffin film and incubate them for 1 h at RT.

7.4. Aspirate the ECM solution from the pre-warmed plates and replace it with 2 mL of PSC medium per well. Do not allow the surface of the wells to dry. Set them aside.

7.5. Aspirate the reprogramming medium from 2 reprogrammed wells on a day when the colonies are large and clearly formed (usually day 18). Rinse once with 1 mL of EDTA and aspirate.

7.6. Add 1 mL of EDTA per well. Incubate for 4 min at 37 °C.

7.7. Gently remove the plate from the incubator and place it in the biosafety cabinet.

Note: At this point, cells may be very loosely adhered and easily dislodged.

7.8. Carefully aspirate EDTA from both wells. Add 3 mL of pre-warmed PSC medium to each well treated with EDTA. Use a cell-scraper to gently but thoroughly dislodge cells from both wells.

7.9. Use a serological pipette to gently pipette the cell suspension and break up large clumps. Do not pipette until all the cell clumps are gone. Preserve iPSC clusters.

Note: Plating large clumps will not affect iPSC colony outgrowth. If there are excessively large cell clumps, simply avoid transferring them into the next dish.

7.10. Using a serological pipette, evenly distribute cells from each EDTA-treated well by pipetting 0.5 mL into each well of the ECM-coated 6-well plate.

Note: Do not combine cells from the reprogrammed wells (*i.e.*, reprogrammed well 1 should be evenly distributed into the first 6-well plate, and reprogrammed well 2 should be evenly distributed into the second 6-well plate).

7.11. Move the plated cells back into the low-O<sub>2</sub> incubator. To evenly distribute cells, shake each plate back-and-forth and side-to-side. Do not swirl. Replace the PSC medium daily.

## **8. Picking iPSC Colonies**

8.1. Pre-warm 15 mL of PSC medium to 37 °C. Coat all wells of a single 6-well plate with hESC-qualified ECM following the manufacturer's instructions. Seal the plates with paraffin film and incubate them for 1 h at RT.

8.2. Aspirate the culture medium from wells being used to collect iPSCs. Rinse once with 1 mL of EDTA and aspirate. Add 1 mL of EDTA per well. Incubate for 4 min at 37°C. While the cells are incubating, aspirate the ECM solution from the pre-warmed plates and replace with 2 mL of PSC medium per well. Set the plates aside.

8.3. Gently remove the plate with iPSCs to be picked from the incubator and place it in the biosafety cabinet.

Note: At this point, cells may be very loosely adhered and easily dislodged.

8.4. Carefully aspirate EDTA. Very gently add 3 mL of pre-warmed PSC medium, taking care not to dislodge iPSC colonies.

8.5. Move the plate to an inverted or dissecting scope to better visualize colonies. Prepare a 1 mL pipette with a sterile tip. Depress the plunger fully, then use the pipette tip to gently scrape a colony while slowly drawing liquid into the tip to collect the colony. Draw as little medium as possible while picking the iPSC colony.

8.6. To transfer the colony, pipette up and down 3-4 times in a single well of the ECM-coated plate from step 8.4. Repeat until 6 colonies have been picked and transferred into individual wells. Pick no more than 2 colonies from any single well if an optional passaging described in step 7 has been performed.

8.7. Use a standard human stem cell protocol to freeze down all remaining wells. Thaw and re-plate frozen stocks if more colonies must be picked later.

## **9. Characterization of iPSCs**

9.1. Perform TRA-1-60 staining for analysis of reprogramming efficiency (day 18).

Note: 2 out of 3 reprogrammed wells are passaged for future colony picking. The remaining well

can be used for TRA-1-60 staining. This procedure can be performed on the laboratory bench top.

9.1.1. Wash the reprogrammed well with 1 mL of PBS. Fix cells with ice-cold methanol at -20°C for 5 min.

9.1.2. Aspirate methanol. Dry the well for approximately 2 min. Be careful not to over-dry. The cells have dried enough when they become a translucent/matte color.

9.1.3. Wash the well 3 times with 1 mL of PBS for 5 min with gentle shaking. During the washes, prepare 3 mL of 3% hydrogen peroxide in PBS.

9.1.4. Aspirate the PBS. Add 2 mL of diluted peroxide solution. Incubate for 15 min at RT with gentle shaking. Prepare 4 mL of the blocking solution: 10% bovine-serum albumin (BSA) in PBS.

9.1.5. Aspirate the peroxide solution. Wash the well 2 times with 1 mL of PBS for 5 min.

9.1.6. Aspirate PBS and add 2 mL of blocking solution into the well. Incubate for 1 h at RT.

9.1.7. Wash the well 3 times with 1 mL of PBS for 5 min with gentle shaking.

9.1.8. Dilute primary anti-TRA-1-60 antibody at 1:100 in the blocking solution supplemented with 0.05% sodium azide. Prepare 1 mL of antibody dilution for 1 well of a 6-well format dish. Add the antibody dilution to the well and wrap the plate with parafilm to avoid evaporation. Incubate overnight at 4 °C with gentle shaking.

Note: If needed, the incubation with the primary antibody can be done for 1 h at RT with gentle shaking. The primary antibody dilution can be re-used up to 5 times.

9.1.9. After incubation with the primary antibody, wash the well 3 times with 1 mL of PBS for 5 min with gentle shaking.

9.1.10. Dilute the secondary anti-mouse HRP-conjugated antibody at 1:200 in the blocking solution. Incubate the well with the secondary antibody dilution for 2 h at RT with gentle shaking.

9.1.11. Aspirate the secondary antibody dilution and wash the well 3 times with 1 mL of PBS for 5 min with gentle shaking.

9.1.12. During the third wash, prepare the substrate solution following the manufacturer's instruction. After the final wash, aspirate PBS. Add 1 mL of the substrate solution and incubate until desired color develops (approximately 10 min).

9.1.13. Aspirate the substrate solution. Rinse the well with water for 5 min while gently shaking.

9.1.14. Count the colonies, if desired. Reprogramming efficiency = (number of colonies) / (number of plated fibroblasts) x 100%.

9.1.15. For long-term storage, aspirate water from the stained plate and air-dry overnight at RT. Seal the dried plate with parafilm and store at 4°C for up to 2 years to assess reprogramming efficiency later.

#### REPRESENTATIVE RESULTS:

It typically takes approximately 5-6 weeks from the initiation of fibroblast reprogramming to freezing of the first vials of iPSCs (**Figure 1**). The reprogramming protocol can be generally categorized into two phases. Phase 1 includes the fibroblast culture and seven transfections, with the reprogramming RNA cocktail performed every 48 h. Phase 2 includes isolation, expansion, and characterization of the iPSC colonies.

Before initiating the protocol, it should be ensured that the fibroblasts to be reprogrammed are of good quality. Healthy fibroblasts should appear spindle-shaped, bipolar, and refractile with a doubling time of approximately 24 h. By day 0, 250,000 cells plated into a 10-cm dish on day -2 should grow to 40-60% confluency (**Figure 1**, day 0) and yield approximately  $6-10 \times 10^5$  cells. Cells proliferating at a slower rate can be compensated for by plating at a higher density on day -2 and on day 0 for reprogramming.

Fibroblasts should appear very sparse following plating into a well of a 6-well format dish for reprogramming (**Figure 2**, day 1). Twenty-four hours following the first transfection, fibroblasts will lose their spindle shape and adopt a more rounded morphology (**Figure 2**, day 2), which is maintained through the remainder of reprogramming. Green fluorescence from mWasabi mRNA should be minimally observable on day 2 and steadily increase in brightness to be clearly visible by day 4. The ability to detect mWasabi fluorescence can depend on scope sensitivity and setup. Cell density will gradually and consistently increase throughout the first three transfections (days 1-6), with an apparent burst in proliferation occurring between days 7 and 8. The cells should appear largely confluent by day 10 (**Figure 2**, day 10). The first iPSC colonies can appear as early as day 11 (**Figure 2**, day 11); however, colonies may not be observable until as late as day 18. Generally, by days 15-18, there will be large and obvious iPSC colonies that are clearly distinct from surrounding, incompletely reprogrammed fibroblasts (**Figure 2**, day 15 and **Figure 3**, day 17). Immunostaining for the pluripotency marker TRA-1-60 can be performed to assess reprogramming efficiency (**Figure 3**, day 17, TRA-1-60). In our experience, most fibroblast lines yield hundreds of colonies per reprogrammed well (**Figure 3**, inset B).

Suboptimal plating density is the most common reason for reduced efficiency of reprogramming in our protocol and is frequently associated with fibroblasts that are diseased, senescent, and/or high-passage. If plating density is too low, there will be large acellular barren patches at the end of reprogramming (**Figure 4C**), and iPSC colonies may not form (**Figure 4D**). Reprogrammed cells should be very confluent by day 14 (compare **Figures 4A** and **4B** to **Figure 2**, day 14). Similarly, if cells are plated too densely or proliferate too quickly, reprogramming efficiency is dramatically reduced.

To maintain homogeneity of patient-derived iPSCs, it is important to expand cell lines from a single colony. Since reprogramming efficiency is very high in our protocol, neighboring iPSC colonies may form in close proximity to and grow into each other (**Figure 3**, days 15-17). This sometimes makes it difficult to mechanically separate a single colony for clonal expansion. We have found that it is helpful to first passage a reprogrammed well and dilute it across a larger culture area. A good passage ratio consists of evenly splitting a reprogrammed 6-well-format plate well across an entire 6-well plate.

Following the dilution passage, iPSCs grow as colonies and are easily distinguishable from fibroblasts (**Figure 5**, day 18). Initially, iPSC colonies may be loosely packed, and individual cells have a relatively large cytoplasmic area. Over the course of 4-7 days, the iPSCs proliferate and form a characteristic tightly-packed colony with defined edges. Individual cells within the colony have a large nuclear fraction with prominent nucleoli (**Figure 5**, day 22). There should be many colonies that form in each well, and only those with classic iPSC morphology should be picked for expansion.

#### FIGURE LEGENDS

**Figure 1: Reprogramming of human fibroblasts into induced pluripotent stem cells (iPSCs).** A schematic protocol for the reprogramming of human fibroblasts is presented. Fibroblasts are first passaged at a low density into a well of a 6-well format dish, followed by seven transfections performed at 48 h intervals. Medium is replaced 16-20 h after each transfection. Reprogrammed iPSCs are first passaged at approximately day 18, and clonal colonies are picked by day 26. Typically, fibroblast-derived iPSC lines can be frozen for long-term storage by day 38.

**Figure 2: Representative daily images during each day of reprogramming.** Fibroblasts should be approximately 40-60% confluent at the time of passage to initiate reprogramming (day 0, cells are plated in a 10 cm dish). The first transfection (T1) occurs on day 1, and the cells should appear very sparse at this point. The following day (day 2), a more rounded morphology should become apparent. Cells will continue to increase in density throughout the protocol with iPSC clusters beginning to appear as early as day 11 (circled in red). By day 15, iPSC colonies will be large with discrete boundaries. Scale bar = 200  $\mu$ m.

**Figure 3: Colony formation following transfections with reprogramming modified mRNAs and miRNA mimics.** Low-magnification images were taken of a representative reprogramming on days 15-17. Following the final transfection, reprogrammed iPSCs will form clear colonies with defined boundaries that expand in size and condense to become clearly distinct from incompletely reprogrammed surrounding fibroblasts. Immunostaining for the pluripotency marker TRA-1-60 indicates the presence of iPSCs (inset A) and can be used for calculation of reprogramming efficiency by counting all colonies within a single well (inset B, examples of countable colonies circled in green). Scale bar = 1 mm.

**Figure 4: Representative images of sub-optimal plating density for reprogramming.** (A, B) Examples of fibroblasts that are too sparse by day 14 of reprogramming (compare to **Figure 2**,

day 14). (C) Low magnification image on day 17 of reprogramming with a large, barren patch circled in red. (D) The same well was fixed and stained for TRA-1-60 to confirm overall poor reprogramming efficiency due to low cell density. Scale bars = 200  $\mu$ m and 1 mm for (A, B) and (C, D), respectively.

**Figure 5: Representative images of iPSCs after initial passage.** After completing transfections with reprogramming modified mRNAs and miRNA mimics, reprogrammed cells are passaged by days 17-20. iPSCs have a growth advantage in PSC medium and rapidly overtake any fibroblasts that were incompletely reprogrammed. Initially, iPSCs will form colonies that may appear loose with poorly defined borders. Within several days, the cells rapidly proliferate and take on the characteristic morphology of tightly packed cells with a high nucleus-to-cytoplasm ratio, tightly clustering into colonies with distinct borders. Scale bar = 200  $\mu$ m.

#### **Table 1: Preparation of transfection mix.**

#### **DISCUSSION:**

This protocol describes a clinically-relevant, non-integrating, RNA-based method that allows for the reprogramming of normal and disease-associated human fibroblast lines into iPSCs at an ultra-high efficiency. To date, every human fibroblast line we have attempted to reprogram with the described protocol has yielded a satisfactory number of high-quality iPSCs for downstream applications. Resulting iPSCs can immediately be transferred and expanded in feeder-free culture conditions.

#### **Quality of fibroblasts for reprogramming:**

Reprogramming success is heavily dependent on the quality of starting fibroblasts. Ideally, reprogramming should be initiated with the lowest passage fibroblasts available to achieve the highest efficiency. Reprogramming efficiency is best with fibroblasts of passage 2-4. Reprogramming can still work with high-passage (passage 5-8), even senescent fibroblasts, albeit with a reduced efficiency. Sometimes low-passage fibroblasts are unavailable or patient samples have a genetic mutation that prevents healthy growth. In this case, optimization of initial plating density may be required. The reprogramming of compromised fibroblast lines is usually associated with increased cell death during RNA transfections. As a result, the cells in the reprogramming well will appear to be sparse by days 10-14 of reprogramming. Large acellular areas will also be visible in the well. If this is the case, the reprogramming protocol will need to be re-initiated with a higher initial starting number of fibroblasts. Plating 3,000 input cells per well of a 6-well format dish works consistently for most adult fibroblast lines. However, increasing the plating number to 5,000-10,000 (50,000 for senescent lines) may help to improve reprogramming of disease-associated samples, as has been reported in our previous publication<sup>8</sup>. Conversely, cells reaching confluency too early can also be resistant to reprogramming. If cells undergoing transfections with reprogramming RNAs proliferate too rapidly (as is sometimes the case with primary neonatal fibroblasts), initiate reprogramming with 500 fibroblasts per well of a 6-well format dish<sup>8</sup>.

#### **Handling of the transfection buffer:**



The pH of the transfection buffer (reduced-serum medium adjusted to the pH of 8.2) is paramount to achieving the optimal transfection efficiencies required for this reprogramming protocol. For this reason, several precautions regarding the handling of the transfection buffer are recommended. We have found that even short exposure of the transfection buffer to atmospheric air affects the pH of the buffer. Therefore, the transfection buffer should be aliquoted into a screw cap container with minimal air space (we use either 5 or 15 mL screw cap conical tubes). To further minimize air exposure, use each transfection buffer aliquot for a maximum of two transfections. Lastly, since temperature impacts pH, it is critical that the transfection buffer is equilibrated to RT for assembly of the transfection complexes. It is advised to not warm the transfection buffer to 37°C.

#### Passaging of iPSCs:

While many previously published protocols recommend picking individual iPSC colonies at the end of reprogramming, this may be difficult to achieve when the efficiency of reprogramming is very high or if the colonies cluster together, as is often the case in our protocol. Therefore, if iPSC colonies are in close proximity to each other, we recommend first passaging the cells to spread out reprogrammed iPSCs before manually picking colonies. There are several advantages to performing this early passage step. Spreading out the colonies gives them more room to grow, yielding much larger colonies for picking than could otherwise be achieved in the original well. This greatly improves the success rate in establishing an iPSC line from a picked clone. We also find that the additional culture time with fibroblasts, albeit at a diluted ratio, appears to improve the average quality of picked iPSC colonies. The incompletely reprogrammed fibroblasts may provide supporting paracrine factors, which continue to help establish the iPSCs and ease the direct transition into feeder-free cell culture conditions. Fibroblasts fortuitously have a selective growth disadvantage compared to iPSCs when cultured in mTeSR1. Therefore, the contaminating fibroblast cell population is quickly diluted to negligible quantities within 3-4 passages.

ROCK inhibitors such as Y-27632 are frequently used for routine culture of human iPSCs. We have found that frequent and/or extended culture of some iPSC lines with Y-27632 can have deleterious effects on overall quality. When using a clump passaging method, such as with EDTA, Y-27632 is not necessary to maintain iPSC viability after splitting. We have completely eliminated supplementing media with Y-27632 for all iPSC isolation, expansion, or routine culture.

#### Protocol limitations:

One limitation to the described RNA-based reprogramming approach is the initial cost and complexity associated with the preparation of the reprogramming reagents. Although preparatory procedures to generate mRNA reagents are all routine and have been previously described (PCR, *in vitro* transcription, DNase treatment, capping, dephosphorylation, purification), cumulatively the production of mRNA reagents is a relatively lengthy and non-trivial process. The other major challenge to this protocol is the need to transfect cells every 48 h, increasing the labor intensity of the reprogramming protocol. These considerations may be prohibitive if reprogramming of only a few patient samples is desired. However, if the primary consideration is the generation of clinically relevant iPSCs or achieving very high reprogramming efficiency, the described RNA-based reprogramming approach is ideal.

In summary, the described high-efficiency RNA-based reprogramming method hinges on optimized transfection efficiency of the somatic cell type to be reprogrammed as described in our previous publication<sup>8</sup>. The RNA transfection protocol presented in this study is highly tuned for human primary fibroblasts but can potentially be tailored to other cell types to improve reprogramming efficiency of various somatic cells.

#### ACKNOWLEDGMENTS:

We are grateful for funding support from the National Institutes of Health (T32AR007411-33) and the University of Colorado Skin Diseases Research Core Center (P30AR057212). We also thank the Epidermolysis Bullosa (EB) Research Partnership, EB Medical Research Foundation, Cure EB Charity, Dystrophic Epidermolysis Bullosa Research Association (DEBRA) International, King Baudouin Foundation's Vlinderkindje Fund, and Gates Frontiers Fund.

#### DISCLOSURES:

I.K. and G.B. are co-inventors on a patent application entitled "Methods and Compositions for Reprogramming Cells", PCT Application No. PCT/US2016/063258.

#### REFERENCES:

1. Takahashi, K., Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell*. **126** (4), 663–676 (2006).
2. Takahashi, K., *et al.* Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. *Cell*. **131** (5), 861–872 (2007).
3. Schlaeger, T.M., *et al.* A comparison of non-integrating reprogramming methods. *Nature Biotechnology*. **33** (1), 58–63 (2015).
4. Hacein-Bey-Abina, S., *et al.* LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. *Science*. **302** (5644), 415–419 (2003).
5. Warren, L., *et al.* Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell*. **7** (5), 618–630 (2010).
6. Judson, R.L., Babiarz, J.E., Venere, M., Bluelloch, R. Embryonic stem cell-specific microRNAs promote induced pluripotency. *Nature Biotechnology*. **27** (5), 459–461 (2009).
7. Anokye-Danso, F., *et al.* Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. *Cell Stem Cell*. **8** (4), 376–388 (2011).
8. Kogut, I., *et al.* High-efficiency RNA-based reprogramming of human primary fibroblasts. *Nature Communications*. **9** (1), (2018).
9. Hirai, H., *et al.* Radical acceleration of nuclear reprogramming by chromatin remodeling with the transactivation domain of MyoD. *Stem Cells*. **29** (9), 1349–1361 (2011).
10. Mandal, P.K., Rossi, D.J. Reprogramming human fibroblasts to pluripotency using modified mRNA. *Nature Protocols*. **8** (3), 568–582 (2013).
11. Avci-Adali, M., *et al.* In vitro synthesis of modified mRNA for induction of protein expression in human cells. *Journal of Visualized Experiments*. e51943 (2014).

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.



This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.

This is an Adobe® Illustrator® File that was saved without PDF Content.

To Place or open this file in other applications, it should be re-saved from Adobe Illustrator with the "Create PDF Compatible File" option turned on. This option is in the Illustrator Native Format Options dialog box, which appears when saving an Adobe Illustrator file using the Save As command.



**Table 1. Preparation of Transfection Mix**

Tube 1 - RNAiMax dilution (1st mix)		
Reagent	Concentration	Volume
Transfection Buffer		279 $\mu$ L
RNAiMax (add 2nd)	10x	31 $\mu$ L
		Total: 310 $\mu$ L

(incubate 1 min at room temperature)

Tube 2 - modified mRNA mix (2nd mix)		
Reagent	Concentration	Volume
modified mRNA mix	100 ng/mL (5x)	33 $\mu$ L
Transfection Buffer		132 $\mu$ L
		Total: 165 $\mu$ L

(add equal volume of diluted RNAiMax from Tube 1)

Tube 3 - miRNA mimics mix (3rd mix)		
Reagent	Concentration	Volume
miRNA mimics mix	5 pmol/ $\mu$ L (8.33x)	14 $\mu$ L
Transfection Buffer		102.6 $\mu$ L
		Total: 116.6 $\mu$ L

(add equal volume of diluted RNAiMax from Tube 1)







1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Highly efficient reprogramming of primary human fibroblasts into induced pluripotent stem cells using modified mRNAs and mature microRNA mimics
Author(s):	Patrick S. McGrath, Nicole Diette, Igor Kogut, and Ganna Bilousova

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access

☒ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Ganna Bilousova	
Department:	Department of Dermatology, Charles C. Gates Center for Regenerative Medicine	
Institution:	University of Colorado School of Medicine, Anschutz Medical Campus	
Title:	Assistant Professor	
Signature:		Date: June 27, 2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

**We thank the reviewers and the editor for the thorough review of our manuscript JoVE58687. Our point-by-point response to the editorial and peer review comments is highlighted in bold.**

Editorial comments:

1. *Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.*  
**We proofread the manuscripts as was suggested. All edits are tracked in the word file.**
2. *Figure 2: Please include a space between the number and its unit (i.e., 10 cm).*  
**The figure has been modified accordingly.**
3. *Please revise the title to be more concise if possible.*  
**We have shortened the title. The new title is: Highly efficient RNA-based reprogramming of human primary fibroblasts into induced pluripotent stem cells.**
4. *Please spell out each abbreviation the first time it is used.*  
**The text has been modified accordingly.**
5. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. For example: Opti-MEM, GlutaMax, Matrigel, Lipofectamine, etc.  
**The text has been modified accordingly, and the general terms were used in the protocol where appropriate.**
6. *Please revise the protocol to contain only action items that direct the reader to do something (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a “Note.” Please include all safety procedures and use of hoods, etc. Please move the discussion about the protocol to the Discussion.*  
**We modified the text accordingly. We moved the text that cannot be written in the imperative tense to “Notes” or Discussion.**
7. *In the JoVE Protocol format, “Notes” should be concise and used sparingly. They should only be used to provide extraneous details, optional steps, or recommendations that are not critical to a step. Any text that provides details about how to perform a particular step should either be included in the step itself or added as a sub-step. Please consider moving some of the notes about the protocol to the discussion section.*  
**We eliminated many “Notes” from the manuscript and shortened the remaining “Notes” where possible.**
8. *Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please*



*ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.*

**We added more details into the protocol.**

9. *1.3.2, 7.1: What is used to filter sterilize?*

**In both cases, “using a 0.22 µm vacuum filtration system” was added.**

10. *1.7: Please specify how to calibrate incubators.*

**Specified now: “Calibrate tissue culture incubators before initiating reprogramming according to the manufacturer’s instruction using a handheld digital CO<sub>2</sub> analyzer, fyrite, or similar system.”**

11. *4.2: Please explain how to monitor mWasabi expression.*

**Added: “using a microscope configured to visualize EGFP.” Inverted microscope capable of visualizing EGFP was also added to the list of required equipment in the Table of Materials.**

12. *1.7 and 1.8, etc.: The Protocol should contain only action items that direct the reader to do something. Please either write the text in the imperative tense as if telling someone how to do the technique (e.g., “Do this,” “Ensure that,” etc.), or move the solutions, materials and equipment information to the Materials Table.*

**The text was modified accordingly. A list of necessary equipment was also added to the Table of Materials.**

13. *Please combine some of the shorter Protocol steps so that individual steps contain 2-3 actions and maximum of 4 sentences per step.*

**The text was modified accordingly.**

14. *After you have made all the recommended changes to your protocol (listed above), please re-evaluate your protocol length. There are a 10 page limit for the Protocol, and a 2.75 page limit for filmable content. Please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.*

**We modified the text of the protocol to fit the requirements of the journal. We have also highlighted ~2.75 pages for the video.**

15. *Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.*

**Highlighted according to the instruction.**

16. *Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.*

**Highlighted according to the instruction.**

17. *Discussion: Please also discuss any limitations of the technique.*

**The protocol limitations section has been added to the discussion.**



## Reviewers' comments:

### **Reviewer #1:**

#### *Manuscript Summary:*

*The authors present a method by which human skin fibroblasts are reprogrammed into induced pluripotent stem cells using a combination of modified RNAs and micro RNAs. The method appears to work very efficiently yielding high numbers of fully reprogrammed clones. I think that this protocol is of interest to the scientific community.*

#### *Minor Concerns:*

*-lines 83/87: The authors state that by using only a few thousand fibroblasts "thereby limiting the total number of cell divisions between isolation and reprogramming" while other strategies require several passages to dilute out the respective reagents. However, from my experience using Sendai virus the fibroblasts are split once prior to successful reprogramming. It is true that one needs several passages to dilute of Sendai virus (usually 5 to 10, depending on the cells). However, this passaging only occurs after successful reprogramming. Therefore, I cannot completely agree with the authors' statement.*

**We apologize for the confusion that our statement caused. We modified the third paragraph of the introduction section and focused on overall time in culture rather than on cell divisions required before the initiation of our protocol.**

*-lines 189/190: Reprogramming medium supplemented with 5% FBS. Does that refer to the reprogramming medium mentioned in lines 179 to 181 to which 5% FBS are added, i.e. 25% serum in the end? Or is this reprogramming medium identical to that mentioned in lines 179 to 181 where the 20% Knockout Serum Replacement are replaced by 5% FBS?*

**We apologize that we did not clarify this in the protocol. The plating medium is prepared by adding 5% HI FBS into reprogramming medium containing 20% KOSR (20%KOSR + 5% HI FBS). We clarified this in section 1.6.**

*-lines 209/210: "ideally, passage number should be below 5". From our experience we find fibroblasts of passage 2 or 3 ideal and we use passage 4 cells rather exceptionally. If that coincides with the authors' experience it might be specified in detail here.*

**We agree with the reviewer that passage 2-3 is the best. However, we still observe a relatively high reprogramming efficiency when high-passage fibroblasts are used. We clarified this in the discussion section in the "Quality of fibroblasts for reprogramming" section.**

*-Section 9 Characterization of hu iPSCs: TRA1-60 is a surface molecule, therefore I wonder why the authors fix the cells instead of performing a live staining?*

**We agree with the reviewer that live staining can be performed. However, cell fixation allows for long-term storage of stained plates and the direct comparison of reprogramming efficiencies among independent reprogramming attempts. We clarified this in 9.1.16.**

*-line 552: The blocking solution contains 1% goat serum, while the secondary anti-mouse HRP-conjugated AB is a rabbit polyclonal. Normally the serum of the species from which the secondary antibody has been derived is used for blocking, i.e. rabbit serum in this case.*

**We would like to thank the reviewer for noticing this discrepancy. For the provided protocol, we do not use any serum for blocking, as 10% BSA is sufficient to eliminate background. Goat serum was included in error during the preparation of the manuscript. The protocol is modified accordingly (section 9.1.4.)**

*-Passaging reprogrammed cells: The authors state that cell lines should derive from a single colony. Due to their high reprogramming efficiency they recommend to split one reprogrammed six well to an entire 6-well plate. Do they have any idea of how many duplicates are generated as I suppose during splitting one colony will be divided into several "sister" colonies?*

**We agree that there is a possibility that sister colonies may be picked. We have not attempted to quantify the number of “sister” colonies generated from an original reprogrammed colony. The reprogramming efficiency is typically very high, and we feel the possibility of accidentally collecting from multiple adjacent reprogrammed colonies is riskier than the possibility of picking redundant sister colonies following the diluting passage. Considering that most reprogramming attempts performed with our protocol generate hundreds of colonies, we feel the chances of expanding two colonies derived from the same parental clone are adequately small. Nevertheless, we clarified that the described passaging strategy is an optional procedure when the colonies cannot be manually separated for direct picking (section 6.3). There are often a few separate colonies in the well that can be directly picked without an additional passage. However, additional passaging provides several advantages as described in the “Passaging of iPSCs” section in Discussion.**

*-lines 256/257: It appears compulsory to use a tri-gas incubator to maintain low oxygen levels. Just by curiosity I wonder how commonly these incubators are used and available as I do not know about any in the laboratories of all our collaboration partners.*

**We have not directly compared our reprogramming approach in a normoxic incubator. While not essential or universally practiced, reprogramming in hypoxic conditions is fairly common among stem cell laboratories and has been previously shown to be more efficient (originally shown to be advantageous by Yoshida et al., Cell Stem Cell, 2009). We expect our protocol to work under normoxic conditions for many fibroblast lines. However, the protocol may result in a lower reprogramming efficiency and may fail to generate iPSCs from cell lines resistant to reprogramming, such as senescent/aged lines.**

## **Reviewer #2:**

### *Manuscript Summary:*

*Here the authors present a reliable protocol for reprogramming fibroblasts using mRNAs and microRNAs. I really appreciate the fact that they throw a whole bunch of reprogramming factors at the problem and don't mess around. Go big or go home! Why should we just use 4 reprogramming factors when several others have been identified? Honestly, I don't like the fact that this protocol involves multiple, frequent transfections, but I guess if that is necessary it can be done. Additionally, I wish these mRNAs were commercially available but maybe they will be at some point. I do like the fact that the authors address hard to reprogram fibroblasts - that is something that is frequently not addressed in these types of papers. In summary, the protocol looks like kind of a pain but it seems to produce high quality iPSCs that have no integration into their genome. I may use this protocol myself - but hopefully I can have a technician do the frequent transfections!*

### *Major Concerns:*

None really

*Minor Concerns:*

*The protocol sounds very labor intensive.*

**We agree that the protocol may be labor-intensive, especially for a laboratory with minimal iPSC and/or mRNA experience. We noted this limitation in the Protocol limitations section in Discussion.**

**Reviewer #3:**

*Manuscript Summary:*

*The authors describe in precise details a protocol for obtaining integration-free human iPSC with a method based on successive transfections of mRNA and miRNA mimics. This method, previously described in \*Kogut, I. et al. High-efficiency RNA-based reprogramming of human primary fibroblasts. Nature Communications. 9 (1)\*, is incomparably more efficient than any other reprogramming method described. Because of this, visual confirmation of the results obtained would add relevant information to the original article.*

*The authors have achieved in this manuscript a high level of detail, which will greatly benefit even experts in the field.*

*In the following review, minor suggestions and interrogations are cited.*

*Major Concerns:*

None

*Minor Concerns:*

111 : *If the authors and editors think it would be relevant, readers of this work in J Vis Exp might be interested in an additional citation of a J Vis Exp report on in vitro synthesis of mRNA :*

*Avci-Adali M, Behring A, Steinle H, Keller T, Krajewski S, Schlensak C, Wendel HP. In vitro synthesis of modified mRNA for induction of protein expression in human cells. J Vis Exp. 2014 Nov 13*

**We added the provided reference in the protocol (reference 11) and noted that it can be used as an alternative protocol for mRNA production.**

138 :

*Number of aliquots of RNA and miRNA : could the authors confirm that if :*

*-each aliquot contains 1000ng RNA (line 132 : 33uLx100ng/uL)*

*-1,000 ng of the modified mRNA cocktail is added per well during each transfection [SEP](line 138)*

*-this protocol is designed for reprogramming 3 wells of human primary fibroblasts [SEP](line 101)*

*-The technique consists in 7 successive transfection (line 402)*

*...there should be 21 aliquots prepared (7 x 3 wells), and not 7 (line 135) ?*

**We apologize for the confusion. The number of aliquots provided in the protocol is correct: 7 x 33  $\mu$ L aliquots of modified mRNAs and 7 x 14  $\mu$ L aliquots of the miRNA mimics mix. Each aliquot is sufficient to prepare a transfection mix for the simultaneous transfection of three wells. We clarified the text of the manuscript by adding “Notes” in “1. Reagents and equipment to prepare prior to initiation of reprogramming.”**

**Note located after 1.1.2:** *“For each transfection, 1,000 ng of the modified mRNA cocktail is added per well (i.e. a total of 3,000 ng for three wells). Each 33  $\mu$ L aliquot is sized to transfect three wells of a 6-well format plate and includes 3  $\mu$ L excess to account for pipetting error. Preparing seven 33  $\mu$ L aliquots is sufficient to complete a full fibroblast reprogramming of three wells in a 6-well format plate.*

**Note located after 1.2.2:** *“For each transfection, 20 pmol of the miRNA mimics mix is added per well (i.e. a total of 60 pmol for three wells). Each 14  $\mu$ L aliquot is sized to transfect three wells of a 6-well format plate and includes 2  $\mu$ L excess to account for pipetting error. Preparing seven 14  $\mu$ L aliquots is sufficient to complete a full fibroblast reprogramming of three wells in a 6-well format plate.”*

144 : Please add a note to provide a reference where these products are found / synthesized in which conditions

**The supplier of miRNA mimics is included in the Table of Materials. In the revised manuscript, we referred the readers to the Table of Materials for the vendor and catalog numbers of miRNAs. See the second sentence in 1.2.1.**

163 : The authors point out that this point is critical : As it is not conventional to adjust the pH of mammalian cell culture medium, it would be beneficial to the reader to describe in the subsequent video the exact conditions of pH adjustment : Adding NaOH, filtering...

**We expanded this section and will include it into the video.**

202 : Is this true for the reprogramming steps (which rely on Laminin521) or only for the subsequent passaging steps (Chapter 7 onwards)

**We deleted this section, so that we do not confuse readers. In the Table of Materials, we indicated that Laminin521 is used for reprogramming, and Matrigel is used for passaging. However, virtually any other ESC-qualified matrix can be used for passaging of generated iPSCs. In the text, we indicated that iPSCs can be cultured by standard protocols (section 6.3), emphasizing that once iPSCs are generated, there are no particular requirements for passaging conditions and each laboratory can implement their own passaging protocols.**

207 : 5% O<sub>2</sub>. As all laboratories do not culture cells in these conditions, do the authors have information on the results expected when using normoxic (20%) conditions ?

**Reviewer 1 asked a similar question. Therefore, we are duplicating our response below:**

**We have not directly compared our reprogramming approach in a normoxic incubator. While not essential or universally practiced, reprogramming in hypoxic conditions is fairly common among stem cell laboratories and has been previously shown to be more efficient (originally shown to be advantageous by Yoshida et al., Cell Stem Cell, 2009). We expect our protocol to work under normoxic conditions for many fibroblast lines. However, the protocol may result in a lower**

**reprogramming efficiency and may fail to generate iPSCs from cell lines resistant to reprogramming, such as senescent/aged lines.**

*259 : visual examples of the confluency of cells are available in Figure 2, a reference to this figure at this point in text would be useful*

**We added a reference to Fig. 2, Day 0 in 2.2.1.**

*263 : the rhLAMININ-521 Ref A29248 is sold as a powder. Please provide the concentration of the solution.*

*Could the authors confirm that at this early stage in the reprogramming process the Laminin-521 is essential and cannot be replaced by Matrigel, Vitronectin... (cf line 202)*

**Although ThermoFisher refers to rhLaminin-521 in µg, the reagents come diluted at a concentration of 100 µg/mL and not as a powder. We indicated the concentration of the matrix in the Table of Materials under Comments.**

*589 : Visual aid would be helpful to determine which colonies should be counted or not (as in original Nat. Comm.)*

**We included an additional panel in Fig. 3 (inset B) as requested. Examples of countable versus not countable colonies are indicated.**

*page 27 Materials :*

*Addgene numbers : are these references up to date (as the plasmids do not yet appear in the catalog)*

**The plasmids have been sent to Addgene and should become available before the publication. The numbers are correct. We will re-validate the numbers one more time before approving the manuscript for publication.**